Deal overview
| Target | IGM BIOSCIENCES INC (RIGHTS TO IGM ANTIBODIES) |
|---|---|
| Bidder | SANOFI SA |
| Price | £50.00 Full version or £25.00 Light version |
| Publication Date | Mar 29, 2022 |
| Abstract | On 29 March 2022, the quoted French pharmaceutical company Sanofi SA ("Sanofi"), announced that its US subsidiary Genzyme Corporation ("GC") had entered into a worldwide collaboration agreement with the quoted US biotechnology company IGM Biosciences, Inc. ("IGM") to create, develop, manufacture, and commercialise IgM antibody agonists against three oncology targets and three ... |
| Number of pages (Full version) | 5 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
